Biontech SE
BNTX107.500USD
-2.550-2.32%
收盤 07/31, 16:00（美東）報價延遲15分鐘
25.84B總市值
虧損本益比TTM
關於 Biontech SE 公司
BioNTech SE 是一家位於德國的臨牀階段生物技術公司。該公司專注於針對癌症和其他嚴重疾病的患者特異性免疫療法。該公司提供的技術包括基於 mRNA 的療法、細胞療法、小分子和抗體，這些技術可用於特定目的，甚至可以以協同方式相互結合。該公司還利用不同的科學方法和技術平臺開發了廣泛的產品線，包括個性化的基於 mRNA 的產品候選物、嵌合抗原受體 T 細胞、檢查點免疫調節劑、靶向癌症抗體和小分子。此外，該公司還爲其他治療領域提供診斷產品和藥物發現服務，包括傳染病、過敏和自身免疫性疾病。
公司簡介
公司代碼BNTX
公司名稱Biontech SE
上市日期Oct 10, 2019
成立日期2019
CEOProf. Ugur Sahin, M.D.
員工數量6772
證券類型Depository Receipt
年結日Oct 10
公司地址An der Goldgrube 12
城市MAINZ
上市交易所NASDAQ Global Select Consolidated
國家Germany
郵編55131
電話4949613190840
網址https://www.biontech.com/
公司代碼BNTX
上市日期Oct 10, 2019
成立日期2019
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Ramon Zapata Gomez
Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
收入明細
單位: EUR更新時間: 3月12日 週三
單位: EUR更新時間: 3月12日 週三
FY2019
FY2018
FY2017
業務EUR
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
暫無數據
業務
地區
業務EUR
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
股東統計
更新時間: 7月19日 週六
更新時間: 7月19日 週六
持股股東
股東類型
持股股東
持股股東
佔比
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
持股股東
持股股東
佔比
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
股東類型
持股股東
佔比
Corporation
60.58%
Investment Advisor
15.28%
Investment Advisor/Hedge Fund
3.60%
Individual Investor
2.11%
Hedge Fund
1.18%
Research Firm
1.17%
Sovereign Wealth Fund
0.75%
Pension Fund
0.23%
Bank and Trust
0.17%
Other
14.94%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
811
205.04M
85.29%
-4.48M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.16M
3.39%
-60.90K
-0.74%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.95M
2.48%
-495.85K
-7.69%
Mar 31, 2025
Flossbach von Storch AG
4.26M
1.77%
-147.21K
-3.34%
Mar 31, 2025
PRIMECAP Management Company
4.05M
1.68%
-249.39K
-5.81%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Mar 31, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Mar 31, 2025
Capital International Investors
1.43M
0.59%
+12.88K
+0.91%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
3.94%
Langar Global HealthTech ETF
3.81%
Global X Genomics & Biotechnology ETF
3.56%
First Trust NYSE Arca Biotechnology Index Fund
3.12%
Franklin Genomic Advancements ETF
2.89%
VanEck Biotech ETF
2.66%
Virtus LifeSci Biotech Products ETF
2.02%
iShares Biotechnology ETF
1.65%
WisdomTree BioRevolution Fund
1.57%
ProShares Ultra Nasdaq Biotechnology
1.21%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比3.94%
Langar Global HealthTech ETF
佔比3.81%
Global X Genomics & Biotechnology ETF
佔比3.56%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.12%
Franklin Genomic Advancements ETF
佔比2.89%
VanEck Biotech ETF
佔比2.66%
Virtus LifeSci Biotech Products ETF
佔比2.02%
iShares Biotechnology ETF
佔比1.65%
WisdomTree BioRevolution Fund
佔比1.57%
ProShares Ultra Nasdaq Biotechnology
佔比1.21%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
